Show simple item record

dc.contributor.authorSarkanen, Tomi
dc.contributor.authorPartinen, Markku
dc.contributor.authorBjorvatn, Bjørn
dc.contributor.authorMerikanto, Ilona
dc.contributor.authorBenedict, Christian
dc.contributor.authorNadorff, Michael R.
dc.contributor.authorBolstad, Courtney J.
dc.contributor.authorEspie, Colin
dc.contributor.authorMatsui, Kentaro
dc.contributor.authorChung, Frances
dc.contributor.authorMorin, Charles M.
dc.contributor.authorWing, Yun Kwok
dc.contributor.authorPenzel, Thomas
dc.contributor.authorMacêdo, Tainá
dc.contributor.authorMota-Rolim, Sérgio
dc.contributor.authorHolzinger, Brigitte
dc.contributor.authorPlazzi, Giuseppe
dc.contributor.authorDe Gennaro, Luigi
dc.contributor.authorLandtblom, Anne-Marie
dc.contributor.authorInoue, Yuichi
dc.contributor.authorSieminski, Mariuz
dc.contributor.authorLeger, Damien
dc.contributor.authorDauvilliers, Yves
dc.description.abstractBackground The COVID-19 pandemic and related restriction measures have affected our daily life, sleep, and circadian rhythms worldwide. Their effects on hypersomnolence and fatigue remain unclear. Methods The International COVID-19 Sleep Study questionnaire which included items on hypersomnolence such as excessive daytime sleepiness (EDS), and excessive quantity of sleep (EQS), as well as sociodemographic factors, sleep patterns, psychological symptoms, and quality of life was distributed in 15 countries across the world from May to September in 2020. Results Altogether responses from 18,785 survey participants (65% women, median age 39 years) were available for analysis. Only 2.8% reported having had COVID-19. Compared to before the pandemic, the prevalence of EDS, EQS, and fatigue increased from 17.9% to 25.5%, 1.6%–4.9%, and 19.4%–28.3% amid the pandemic, respectively. In univariate logistic regression models, reports of having a COVID-19 were associated with EQS (OR 5.3; 95%-CI 3.6–8.0), EDS (2.6; 2.0–3.4), and fatigue (2.8; 2.1–3.6). In adjusted multivariate logistic regression, sleep duration shorter than desired (3.9; 3.2–4.7), depressive symptoms (3.1; 2.7–3.5), use of hypnotics (2.3; 1.9–2.8), and having reported COVID-19 (1.9; 1.3–2.6) remained strong predictors of EDS. Similar associations emerged for fatigue. In the multivariate model, depressive symptoms (4.1; 3.6–4.6) and reports of having COVID-19 (2.0; 1.4–2.8) remained associated with EQS. Conclusions A large increase in EDS, EQS, and fatigue occurred due to the COVID-19 pandemic, and especially in self-reported cases of COVID-19. These findings warrant a thorough understanding of their pathophysiology to target prevention and treatment strategies for long COVID condition.en_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.titleAssociation between hypersomnolence and the COVID-19 pandemic: The International COVID-19 Sleep Study (ICOSS)en_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.rights.holderCopyright 2023 The Author(s)en_US
dc.source.journalSleep Medicineen_US
dc.identifier.citationSleep Medicine. 2023, 107, 108-115.en_US

Files in this item


This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal